Stents liberadores de medicamentos en enfermedad coronaria multivaso (dos y tres vasos)

Abstract

Drug-eluting stents (DES) have significantly decreased clinical restenosis compared with bare metal stents (BMS). Furthermore, the changes made in the latest-generation DESs have led to an additional reduction in the need for repeat revascularization, and in thrombosis rates, with respect to first-generation DESs. This improvement in the safety and efficacy of second-generation DESs should lead to better results in percutaneous coronary interventions, but to date, most of the available evidence with regard to revascularization in the subgroup of patients with multivessel coronary disease (two and three vessels) comes from balloon angioplasty with BMSs and first generation DESs. The available evidence is presented, and recommendations made based on this evidence.